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Abstract
We evaluated the ability of one-month follow-up con-
trast-enhanced ultrasound (CEUS) with second-genera-
tion contrast agent in monitoring radio frequency
ablation (RFA) and transcatheter arterial chemoembo-
lization (TACE) treatments of hepatocellular carcinoma
(HCC). One-hundred forty-eight HCCs were studied
using CEUS: 110 nodules were treated with RFA [41/110
RFA were performed using a pretreatment and an
immediate postablation evaluation using CEUS (group
1); 69/110 using only US guidance (group 2)] and 38
nodules treated with TACE. For statistical analysis,
McNemar test was used. Overall complete response was
observed in 107/148 nodules (92/110 treated with RFA
and 15/38 with TACE). A better rate of complete re-
sponse was found in group 1 compared to group 2
(92.7% vs. 78.3%). In RFA treatment, CEUS showed a
sensitivity of 83.3% and a speciﬁcity of 100% (diagnostic
accuracy of 97%) using MDCT as reference standard
with no statistical difference (p > 0.05). CEUS detected
all cases of incomplete response in HCC treated with
TACE using angiography as reference standard (diag-
nostic accuracy 100%). We recommend assessing residual
intratumoral flow on CEUS during RFA procedure to
determine the necessity of immediate additional treat-
ment. In case of positive CEUS results, HCC treated
with TACE should be considered still viable.
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Hepatocellular carcinoma (HCC) has an incidence which
is increasing worldwide, represents more than 5% of all
cancers, and estimated annual number of cases exceeds
500,000 [1].
If diagnosed at an early stage, patients should be
considered for surgical resection and liver transplan-
tation, which are considered to be potentially curative
options; however, less than 30% of cases are candi-
dates to surgery at the time of diagnosis due to ad-
vanced tumor stage and underlying liver cirrhosis [2].
For this condition, many patients should be consid-
ered for nonsurgical treatment such as radiofrequency
ablation (RFA), transcatheter arterial chemoemboli-
zation (TACE), percutaneous ethanol injection, etc.
[1].
Accuracy in assessing treatment response is essential
for determining the necessity of additional therapy to
complete the treatment.
Multiphasic multidetector CT (MDCT) is one of the
most commonly used modalities for assessing the thera-
peutic response to nonsurgical treatment in patients with
HCC [3–5].
Several authors have applied contrast-enhanced
ultrasound (CEUS) to evaluate the therapeutic
response in HCCs treated with nonsurgical procedures
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However, many authors used a ﬁrst-generation con-
trast agent that has several procedural limits: in fact,
interval-delay scanning or manual ﬂash imaging is nec-
essary. These limits were overcome by the introduction
of second-generation contrast agents that allow real-time
imaging during different vascular phases [10, 11].
Moreover, it has been proposed to use CEUS before,
during, and immediately at the end of RFA procedure to
assess the therapeutics results prior to closing the treat-
ment session [12].
Aim of this prospective study was to assess the reli-
ability of ultrasonography with a second-generation
ultrasound contrast agent in evaluating HCC treated
with TACE and RFA guided and monitored with CEUS.
Methods
Patients
Institutional Review Board. The study protocol was ap-
proved by the Local Ethics Committee; written informed
consent was obtained before study inclusion from all
patients.
Population. From February 2005 to December 2007, 162
consecutive patients [age range 43–75 years, mean age
59 ± 8.4 (standard deviation) years] were referred to our
Radiology Department to perform 1-month CEUS and
MDCT examination for follow-up of nonsurgical-treated
HCC.
Of 162 patients, 120 were treated with RFA and 42
were treated with TACE.
Inclusion and exclusion criteria. An inclusion criterion
was a single treatment with RFA or TACE.
Exclusion criteria were the lack of identiﬁcation of the
HCC in gray-scale sonography and contraindication to
iodinated contrast agents (allergic reactions; impaired
renal function).
Excluded patients were: 14 for a history of multiple
treatments with TACE or RFA, 7 for the lack of iden-
tiﬁcation of the HCC in gray-scale sonography, and 2 for
contraindication to iodinated contrast agents (allergic
reactions, n = 1; impaired renal function, n = 1).
Study population. Of the total study population, 110
patients underwent RFA and 29 patients underwent
TACE treatment.
In 9 patients with multiple-treated HCC (all treated
with TACE), the two largest lesions were selected for this
study. The other 130 patients had a single-treated HCC.
Thus, a total of 148 nodules (110 treated with RFA and
38 nodules treated with TACE) were pooled for the study.
Treatment design. The medical records of the study
population related to RFA design were reviewed by a
radiologist.
In 41 of the 110 patients RFA treatments were per-
formed using a pretreatment and an immediate postab-
lation evaluation of the targeted HCC using CEUS. If
even questionable residual tumor foci with enhancement
or vascular supply were depicted, immediate CEUS-
guided targeted re-treatment was carried out. These 41/
110 radio frequency-ablated HCCs constituted group 1.
In 69 of the 110 patients RFA treatments were per-
formed using real-time US guidance and the immediate
postablation evaluation using CEUS was not performed.
These 69/110 radio frequency-ablated HCC constituted
group 2.
A ﬂow diagram of patients’ selection and treatment
design is shown in Fig. 1.
CEUS examination
All recruited subjects were evaluated with CEUS tar-
geted to the index lesion.
Patients were scanned using an HDI 5000 scanner
(Advanced Technology Laboratories, Bothell, WA) with
a convex array probe (5-2 MHz) and a ProSound SSD-
5500 scanner (Aloka, Tokyo, Japan) with a convex array
probe (5-2 MHz). Pulse inversion harmonic imaging
(PIHI) with low mechanical index (MI < 0.09) and pure
harmonic detection with low mechanical index
(MI < 0.08) were used.
Prior to injection of the contrast agent, a scanning
plane displaying both the tumor and some surrounding
liver parenchyma with fundamental B-mode was chosen
before switching to contrast-dedicated software.
CEUS was performed using sulfur hexaﬂuoride mi-
crobubbles (SonoVue, Bracco, Milan). A bolus of
2.4 mL of SonoVue was injected by hand via a 20-
gauge intravenous cannula placed in the right antecubital
vein at a rate of approximately 1 mL/s, followed by a 5-
mL normal saline ﬂush.
After SonoVue injection, tumor was scanned for
enhancement for 180 s with the patients holding their
breath for a few seconds if necessary (observation of
arterial, portal, and equilibrium phases).
MDCT examination
Four-phase helical CT, including both nonenhanced and
contrast-enhanced three-phase imaging was performed
with multidetector row CT with four detectors (MX
8000, Philips Medical System, Eindhoven, the Nether-
lands). The images were obtained in the cranio-caudal
direction, from the lower chest to the level of the iliac
crest. The scanning parameters were 120 kVp, 200 mAs,
slice thickness 6.5 mm, and pitch of 1.
CT scans were obtained: ﬁrst at 30–35 s (arterial
phase), at 70–75 s (portal phase), and than at 180 s (late
phase) after intravenous injection of contrast material.
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A nonionic contrast agent material, 120–140 mL of
iopromide (Ultravist 370, Schering, Berlin, Germany),
was administered via a mechanical power injector (MK-
IV Medrad, Pittsburgh, PA) via a 20-gauge intravenous
cannula placed in an antecubital vein at a rate of 4–
5 mL/s.
Image analysis
To minimize the procedural variations, CEUS was per-
formed by the same physician by using the same exam-
ination protocol. The imaging data were recorded on
videotapes or on ultrasound device hard disk and re-
viewed by two independent experienced specialists, one
being the radiologist who performed the examination.
The two readers were blinded to each other’s ﬁndings.
Differences in detection of nodules enhancement were
resolved by consensus. The interobserver agreement be-
tween two blinded readers was also evaluated.
Positive enhancement was deﬁned as strong gray-
scale enhancement appearing within the tumor. Positive
enhancement was interpreted as viable tumor in treated
nodules (incomplete response). In contrast, no enhance-
ment of the lesion was deﬁned as no-bubble signal within
the tumor while the surrounding liver parenchyma was
ﬁlled with bubble signals. No enhancement was inter-
preted as complete tumor necrosis (complete response).
CEUS ﬁndings were compared with ﬁndings at
MDCT by one radiologist.
At MDCT, a radiologist evaluated tumor enhance-
ment by using the comparison of all triple-phase dynamic
CT scans with nonenhanced CT scans. The radiologist
did not have knowledge of the CEUS results. The
interpretation of CT scans was performed by using ﬁlm
copies retrospectively.
Evaluations of treatment response on MDCT scans
were as follows:
– RFA: a complete response was diagnosed when a
hypoattenuating area portraying nonenhancement was
present in both the arterial and portal venous phases in
nodules after treatment. Conversely, an incomplete
response was diagnosed when enhanced areas in the
arterial phase within the tumor were present in
nodules.
– TACE: a complete response was diagnosed when a
complete homogeneous retention of iodized oil was
present; incomplete response was diagnosed when
incomplete retention of iodized oil with hypoattenu-
ating areas showing enhancement was present in the
arterial phase.
Fig. 1. Flow chart of study population.
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Reference standard
One-month MDCT was used as reference standard in the
evaluation of HCC that underwent RFA.
In HCC treated with TACE with incomplete re-
sponse, an angiography with an additional TACE
treatment was performed. In these cases, angiography
was used as reference standard.
Statistical analysis
Sensitivity, speciﬁcity, positive and negative predictive
values, and diagnostic accuracy of CEUS after RFA and
of CEUS and MDCT after TACE at 1 month were cal-
culated.
Posttreatment tumor vascularity was compared with
the gold standard (MDCT for RFA treatment and
angiography for TACE treatment) by means of McNe-
mar test; results are expressed as point estimates and 95%
conﬁdence intervals (95% CI).
Interobserver agreement was evaluated by means of
k-coefficient. Statistical significance was set at 0.05, for a
two-sided test.
The analysis was performed with the Statistical
Analysis System (SAS) software package, Version 8.20
(SAS Institute, Cary, NC).
Results
All patients tolerated the ultrasound contrast agent as
administered without signs of adverse reactions or side
effects.
Treatment response
Overall, in 107 nodules, a complete response was ob-
served (Fig. 2), whereas the other 41 nodules showed an
incomplete response (Fig. 3).
The percentage of complete response was signiﬁcantly
higher in patients who underwent RFA than in those
undergoing TACE (92/110–83.6% vs. 15/38–39.4%;
McNemar test = 46.3; 1 df; p < 0.05).
When considering only RFA, there were complete
responses in both group 1 [38/41 (92.7%)] and group 2
[54/69 (78.3%)], with a statistically signiﬁcant difference
(McNemar test = 45.6; 1 df; p < 0.0001).
Accuracy of CEUS to deﬁne RFA efﬁcacy
CEUS performed 1 month after treatment detected 15 of
18 incomplete response. This represents a sensitivity of
83.3%, speciﬁcity of 100%, positive predictive value of
100%, and negative predictive value of 96.8%.
For HCC treated with RFA, results of CEUS agreed
with those of the reference standard (MDCT) in 107/110
nodules, thus reaching a diagnostic accuracy of 0.97
(95% CI: 0.92–0.99) with no statistical difference
(McNemar test v2 = 1.33; 1 df, p > 0.05).
The agreement with the reference standard was 100%
(41/41) inRFAgroup 1 and 95.6% (66/69) inRFAgroup 2.
Disagreement was due to the presence of three false-
negative results on CEUS: two of three false-negative
results were obtained in tumor deeply located, the other
one in a subcapsular lesion located in segment 7 and not
in a deep location (Fig. 4).
Accuracy of CEUS to deﬁne TACE efﬁcacy
MDCT performed 1 month after treatment detected 20
of 23 incomplete response. This represents a sensitivity of
86.9%, speciﬁcity of 100%, positive predictive value of
100%, and negative predictive value of 83.3%.
CEUS performed 1 month after treatment detected
all cases of incomplete response.
For HCC treated with TACE, results of CEUS and
MDCT agreed with those of the reference standard
(angiography) in 38/38 nodules (100%) [diagnostic
accuracy 1 (95% CI: 0.91–0.99)] and in 35/38 (92.1%)
nodules [diagnostic accuracy 0.92 (95% CI: 0.79–0.97)],
respectively. No statistically signiﬁcant differences be-
tween CEUS and angiography and between MDCT and
angiography (McNemar test v2 = 1.33; 1 df, p > 0.05)
were found.
Fig. 2. Sixty-five-year-old woman with HCC treated with TACE therapy. (A) Nonenhanced CT scan and (B) arterial phase CT
scan show a complete homogeneous retention of iodized oil (arrow). (C) CEUS shows no enhancement within the lesion (arrow).
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Disagreement was due to the presence of three false-
negative results on MDCT. These three lesions showed
a complete homogeneous retention of iodized oil
(Fig. 5).
The 23 nodules treated with TACE which showed
incomplete response (20 showed on MDCT and CEUS
and 3 on CEUS exclusively) underwent an additional
TACE treatment (45–60 days), which resulted in a
complete necrosis.
Interobserver agreement
Disagreement was observed in the analysis of only four
nodules; however, by reviewing videotapes or video clips,
Fig. 3. Fifty-eight-year-old man with HCC treated with RFA
therapy. (A) Nonenhanced CT scan, (B) arterial phase CT
scan, and (C) CEUS (arterial phase) show positive
enhancement (arrowhead) in the lower portion of the nodule
(viable tumor) and no enhancement (arrow) in the upper part
of lesion, respectively.
Fig. 4. Fifty-eight-year-old man with HCC treated with RFA
therapy. (A) Arterial phase CT scan shows hypervascular rim
(arrowhead) of viable tumor in a nonenhancing hypodense
portion of tumor (arrow) adequately ablated. (B) Late-phase
CT scan shows washout of the hypervascular rim (arrowhead)
confirming the presence of viable tumor. (C) CEUS (arterial
phase) shows no enhancement within the lesion (arrow).
Fig. 5. Sixty-three-year-old man with HCC treated with
TACE therapy. (A) Nonenhanced CT scan and (B) arterial
phase CT scan show complete retention of iodized oil within
the nodule (arrow), which suggests a complete response to
TACE therapy. (C) After CEUS, a strong gray-scale
enhancement (arrow) appears within the tumor in arterial
phase.
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a consensus was obtained. The kappa coefﬁcient for
interobserver variability for CEUS evaluation was 0.93
(95% CI: 0.86–1.00), suggesting an excellent agreement.
Discussion
In our series, HCCs treated with RFA showed a com-
plete response in 83.6% of cases. This was a lower rate
than reported in several previous studies, in which it was
varying between 86% and 96% [13–16]. An explanation
for this difference could be that all these studies
(including ours) are inhomogeneous with regard to
technology, treatment protocol, and follow-up period.
For example, immediate postablation evaluation using
CEUS and subsequent immediate CEUS-guided targeted
re-treatment drastically increases the rate of complete
response: in our series, by using this technique, a com-
plete response was obtained in 92.7% (group 2) vs. 78.3%
(group 1). This is not surprising; in fact, several studies
reported that the introduction of intraoperative CEUS
led to a reduction of the rate of partially unablated tu-
mors (i.e., from 16.1% to 5.9% in the study of Solbiati
et al. [12]).
The reported recurrent free rates of HCC treated by
TACE were 28.3–67.5%. These results are strictly
dependent on the number of repetition of TACE treat-
ment, on tumor size, and on follow-up examination time
[17–19]. In the study of Miraglia et al. [19], a single
TACE procedure was sufficient to induce a complete
tumor necrosis only in 69 of 162 (43%) patients.
According to this result, our rate of complete necrosis
after a single TACE treatment was 39.4%.
After treatment with RFA, 15 of 18 cases of treat-
ment failure were correctly identiﬁed using CEUS. We
found a close correlation between ﬁndings of CEUS and
those of MDCT in revealing the outcome of thermal
ablation treatment of HCC lesions. In all patients with a
complete tumor response that was visible on MDCT
images, viable tumors were no longer detectable on
CEUS.
In 3 of the 18 cases of treatment failure, areas of
viable tumor, which closely matched portions of tumor
showing persistent enhancement on MDCT scans, were
not revealed by CEUS.
Several studies [7, 20] showed that tumor location
limited the visualization of lesions by CEUS. We believe
that lesion location may have affected the results in the
three false-negative cases; in fact, of these three lesions,
one was subcapsular lesion and the other two were dee-
ply seated lesions with a depth more than 6 cm from the
transducer.
Regarding accuracy of CEUS to deﬁne TACE efﬁ-
cacy, our results show that MDCT was less sensitive for
detecting residual vascular enhancement in HCC nodules
after TACE than either sonographic method. CEUS
accurately revealed the enhancement from the residual
viable portion (incomplete response) in all cases of the
examined HCC nodules after TACE. MDCT and CEUS,
compared with angiography, showed a sensitivity of
86.9% and 100% in identifying the presence of residual
tumor, respectively.
Three of the 38 nodules that showed no enhancement
on MDCT appeared partially enhanced on CEUS,
whereas no nodule without enhancement on CEUS ap-
peared partially enhanced on MDCT; three false-nega-
tive cases at MDCT were found compared with CEUS
that detected all cases of incomplete response. Digital
angiography examination of the three false-negative
MDCT nodules conﬁrmed the incomplete response.
The detection of the intratumoral blood ﬂow after the
chemoembolization using CEUS were much superior to
the rates of detection using MDCT because the tumor
depiction on CEUS is less affected by iodized oil reten-
tion. High signals caused by accumulated Lipiodol (can
mask enhancement of residual tumor) makes it difﬁcult
to evaluate treatment response and constitute the most
important disadvantage that affects MDCT. The three
false-negative cases found at MDCT showed a complete
homogeneous retention of iodized oil.
A speciﬁc limitation of this study lies in the use of an
imperfect reference standard (imperfect reference bias).
The reference-standard procedures (MDCT in case of
RFA treatment and angiography in case of TACE
treatment) yield results that are not nearly 100% accurate
in detecting recurrent HCC. When compared with his-
topathologic ﬁndings, MDCT sensitivity and speciﬁcity
are,, respectively, 36% and 100% [21], whereas angiog-
raphy shows diagnostic efficacy in detecting recurrent
HCC after TACE of 47% [22]. We think, however, that
MDCT and angiography yields results that are consistent
with clinical objective (response to treatment).
Conclusion
In summary, we found that CEUS enables radiologists to
conﬁdently assess the therapeutic effect of nonsurgical
treatment on HCC.
We highly recommend assessing residual intratumoral
ﬂow on CEUS during RFA procedure to determine the
necessity of immediate additional treatment. This ap-
proach should reduce the costs and allow achieving
optimal patients’ management and treatment results.
In our opinion, CEUS could be considered the exam
of ﬁrst choice in monitoring the efﬁcacy of TACE. We
think that, in the case of CEUS viable tumor ﬁndings,
the HCC nodule treated with TACE should be consid-
ered still viable and undergo an additional treatment
without further CT assessment.
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